Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/99746
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorSchool of Nursingen_US
dc.creatorAbu-Odah, H-
dc.creatorMolassiotis, A-
dc.creatorLiu, JYW-
dc.date.accessioned2023-07-19T00:55:23Z-
dc.date.available2023-07-19T00:55:23Z-
dc.identifier.urihttp://hdl.handle.net/10397/99746-
dc.language.isoenen_US
dc.publisherFrontiers Research Foundationen_US
dc.rights© 2023 Abu-Odah, Molassiotis and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.rightsThe following publication Abu-Odah, H., Molassiotis, A., & Liu, J. Y. W. (2023). A distress thermometer with a cutoff score of≥ 6 is the optimal point to identify highly distressed patients with advanced cancer stages in resource-limited countries without palliative care services. Frontiers in Oncology, 13, 970164 is available at https://doi.org/10.3389/fonc.2023.970164.en_US
dc.subjectAdvanced cancer patientsen_US
dc.subjectDistress thermometeren_US
dc.subjectHealthcare systemen_US
dc.subjectPalliative careen_US
dc.subjectScreeningen_US
dc.titleA distress thermometer with a cutoff score of ≥ 6 is the optimal point to identify highly distressed patients with advanced cancer stages in resource-limited countries without palliative care servicesen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume13en_US
dc.identifier.doi10.3389/fonc.2023.970164en_US
dcterms.abstractPurpose: Although the distress thermometer (DT) scale has been widely validated and used in different cancer types and settings, an optimal cutoff score of DT is not defined to screen advanced cancer patients. The study aimed to define the optimal DT’s cutoff score among advanced cancer patients in resource-limited countries without palliative care services and to assess the prevalence and factors associated with psychological distress among this population.en_US
dcterms.abstractMethods: A secondary analysis was performed. Three hundred seventy-nine patients were recruited from Palestine. Participants completed the DT and the Hospital Anxiety and Depression Scale (HADS). Receiver operating characteristic analysis (ROC) was used to define the optimal cutoff score for the DT against HADS-Total ≥15. Multiple logistic regression was utilized for identifying the factors associated with psychological distress of the DT.en_US
dcterms.abstractResults: A DT cutoff score ≥ 6 correctly identified 74% of HADS distress cases and 77% of HADS non-distress cases, with a positive predictive value (PPV) and negative predictive value (NPV) of 97% and 18%, respectively. The prevalence of distress was found to be 70.7%, and the major sources of distress were related to physical (n = 373; 98.4%) and emotional problems (n = 359; 94.7%). Patients with colon (OR = 0.44, 95% CI: 0.31 – 0.62) and lymphoid cancers (OR = 0.41, 95% CI: 0.26 – 0.64) were less likely to have psychological distress than patients with other types of cancer, whereas patients with lung (OR = 1.80, 95% CI: 1.20 – 2.70) and bone cancers (OR = 1.75, 95% CI: 1.14 – 2.68) were more likely to experience it.en_US
dcterms.abstractConclusion: A cutoff DT score of 6 appeared acceptable and effective for screening distress in patients with advanced cancer stages. Palestinian patients exhibited a high level of distress, and the high prevalence supports the argument of using a DT within the standard delivery of cancer care to identify highly distressed patients. These highly distressed patients should then be involved in a psychological intervention programme.en_US
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationFrontiers in oncology, 15 Mar. 2023, v. 13, 970164en_US
dcterms.isPartOfFrontiers in oncologyen_US
dcterms.issued2023-03-15-
dc.identifier.scopus2-s2.0-85151391149-
dc.identifier.eissn2234-943Xen_US
dc.identifier.artn970164en_US
dc.description.validate202307 bckwen_US
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumbera2275, a2793-
dc.identifier.SubFormID47301, 48375-
dc.description.fundingSourceSelf-fundeden_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
fonc-13-970164.pdf900.34 kBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

70
Citations as of Apr 14, 2025

Downloads

30
Citations as of Apr 14, 2025

SCOPUSTM   
Citations

10
Citations as of Dec 19, 2025

WEB OF SCIENCETM
Citations

3
Citations as of Jan 9, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.